Tumor-reactive T helper cells in the context of vaccination against glioma

Binghao Zhao; Michael Kilian; Theresa Bunse; Michael Platten; Lukas Bunse

doi:10.1016/j.ccell.2023.09.013

Tumor-reactive T helper cells in the context of vaccination against glioma

Cancer Cell. 2023 Nov 13;41(11):1829-1834. doi: 10.1016/j.ccell.2023.09.013. Epub 2023 Oct 19.

Authors

Binghao Zhao¹, Michael Kilian¹, Theresa Bunse¹, Michael Platten², Lukas Bunse³

Affiliations

¹ CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany; German Cancer Consortium (DKTK), DKFZ, core center, Heidelberg, Germany.
² CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Germany; Helmholtz Institute of Translational Oncology Mainz (HI-TRON Mainz) - a Helmholtz Institute of the DKFZ, Mainz, Germany; German Cancer Consortium (DKTK), DKFZ, core center, Heidelberg, Germany; Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, a partnership between DKFZ and University Hospital, Heidelberg, Germany.
³ CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neuroscience, Heidelberg University, Mannheim, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Germany; German Cancer Consortium (DKTK), DKFZ, core center, Heidelberg, Germany. Electronic address: l.bunse@dkfz.de.

PMID: 37863064
DOI: 10.1016/j.ccell.2023.09.013

Abstract

With the advances in immunogenomics, the majority of tumor-specific antigens were found to be recognized by T helper cells (T_HCs). This observation led to the development of long epitope vaccines in various cancers. Mechanistically, we are still gaining a deeper understanding of the mode of action of T_HCs as precision antitumor agonists. Here, we discuss the specific cellular mechanisms of T_HC functions in glioma immunology and contextualize current advances in anti-glioma vaccination exploiting T_HCs.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antigens, Neoplasm
Cancer Vaccines*
Epitopes
Glioma*
Humans
T-Lymphocytes, Helper-Inducer
Vaccination

Substances

Antigens, Neoplasm
Epitopes
Cancer Vaccines